XML 30 R109.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements (Narrative) (Details)
€ in Millions
12 Months Ended
Dec. 29, 2019
USD ($)
Dec. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jan. 03, 2016
USD ($)
Dec. 29, 2019
EUR (€)
Sep. 17, 2019
USD ($)
Sep. 12, 2019
USD ($)
Dec. 30, 2018
EUR (€)
Apr. 11, 2018
USD ($)
Jan. 01, 2017
USD ($)
Jul. 19, 2016
USD ($)
Jul. 19, 2016
EUR (€)
Sep. 30, 2012
USD ($)
Oct. 25, 2011
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 57,100,000                          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 35,481,000 $ 69,661,000 $ 65,328,000             $ 63,201,000        
Long-term Debt $ 2,074,015,000                          
Business Combination, Contingent Consideration Arrangements, Maximum Period 3 years                          
Business Combination, Contingent Consideration Arrangements, Weighted Average Period 1 year 2 months 12 days                          
Payments for acquisition related contingent consideration $ (29,942,000) (12,800,000) $ (8,940,000)                      
Line of Credit, Maturing September 17, 2024 [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Unsecured revolving credit facility, amount           $ 1,000,000,000.0                
Long-term Debt 322,021,000                          
Revolving credit facility outstanding balance 325,400,000                          
Unamortized Debt Issuance Expense 3,400,000                          
Other Debt Facilities - EUROIMMUN [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €         € 25.6                  
Long-term Debt, Percentage Bearing Variable Interest, Amount | €         € 0.1                  
Line of Credit, Maturing August 11, 2021 [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Long-term Debt   415,600,000                        
Revolving credit facility outstanding balance   418,000,000.0                        
Unamortized Debt Issuance Expense   2,400,000                        
2021 Notes [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Unsecured senior notes, face value                           $ 500,000,000.0
Long-term Debt   497,400,000                        
Debt Instrument, Interest Rate, Stated Percentage                           5.00%
Discount on senior unsecured notes   (1,100,000)                       $ (3,100,000)
Unamortized Debt Issuance Expense   1,600,000                        
Financing Lease Obligations [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Other Long-term Debt                         $ 29,300,000  
Finance Lease, Liability   34,500,000                        
1.875 Percent Ten Year Senior Unsecured Notes [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Long-term Debt 552,194,000 564,500,000                        
Debt Instrument, Interest Rate, Stated Percentage                     1.875% 1.875%    
Discount on senior unsecured notes (3,500,000) (4,000,000.0)                 $ (4,400,000)      
Unamortized Debt Issuance Expense 3,300,000 3,800,000                        
0.6 Percent Senior Unsecured Notes due in April 2021 [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Long-term Debt 334,176,000                          
Debt Instrument, Interest Rate, Stated Percentage                 0.60%          
Discount on senior unsecured notes (100,000) (100,000)             $ (200,000)          
Unamortized Debt Issuance Expense   2,000,000.0                        
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Unsecured senior notes, face value             $ 850,000,000.0              
Long-term Debt 839,880,000                          
Debt Instrument, Interest Rate, Stated Percentage             3.30%              
Discount on senior unsecured notes (2,700,000)           $ (2,800,000)              
Unamortized Debt Issuance Expense 7,400,000                          
Unsecured senior notes, fair value $ 872,300,000                          
Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Debt Instrument, Interest Rate, Stated Percentage 1.10%       1.10%                  
Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Debt Instrument, Interest Rate, Stated Percentage 21.50%       21.50%                  
Vanadis Diagnostics AB [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Payments to Acquire Businesses, Net of Cash Acquired       $ 32,000,000.0                    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       93,000,000.0                    
Payment for Contingent Consideration Liability, Financing Activities $ 29,900,000 12,800,000                        
Payment for Contingent Consideration Liability, Operating Activities 20,900,000 3,700,000                        
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value 19,000,000.0     $ (56,900,000)                    
Payments for acquisition related contingent consideration $ 50,900,000 16,500,000                        
Vanadis Diagnostics AB [Member] | Minimum [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Projected milestone date       2016                    
Conditional probability of success 95.00%     85.00% 95.00%                  
Cumulative probability of success       53.00%                    
Vanadis Diagnostics AB [Member] | Minimum [Member] | Measurement Input, Discount Rate [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Measurement Inputs, Discount Rate 3.50%     3.10%                    
Vanadis Diagnostics AB [Member] | Maximum [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Projected milestone date 2020     2019                    
Conditional probability of success 98.00%     95.00% 98.00%                  
Cumulative probability of success       90.00%                    
Vanadis Diagnostics AB [Member] | Maximum [Member] | Measurement Input, Discount Rate [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Measurement Inputs, Discount Rate 4.40%     11.30%                    
Fiscal Year 2019 Other Acquisitions [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value $ 634,000                          
Euro Member Countries, Euro | Other Debt Facilities - EUROIMMUN [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Other Long-term Debt | €         € 21.3     € 28.0            
Euro Member Countries, Euro | 1.875 Percent Ten Year Senior Unsecured Notes [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Unsecured senior notes, face value | €                       € 500.0    
Unsecured senior notes, fair value 518,500,000 496,100,000                        
Euro Member Countries, Euro | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Unsecured senior notes, face value                 $ 300,000,000.0          
Unsecured senior notes, fair value $ 301,900,000 300,500,000                        
United States of America, Dollars | Other Debt Facilities - EUROIMMUN [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Other Long-term Debt | €         23.8     32.1            
Long-term Debt, Percentage Bearing Fixed Interest, Amount | €         € 23.7                  
United States of America, Dollars | Minimum [Member] | Other Debt Facilities - EUROIMMUN [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Debt Instrument, Interest Rate, Stated Percentage 1.10%       1.10%                  
United States of America, Dollars | Maximum [Member] | Other Debt Facilities - EUROIMMUN [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Debt Instrument, Interest Rate, Stated Percentage 4.30%       4.30%                  
United States of America, Dollars | Fiscal Year 2018 Other Acquisitions [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value   6,500,000                        
United States of America, Dollars | Fiscal Year 2019 Other Acquisitions [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value $ 12,700,000                          
Fair Value, Inputs, Level 2 [Member] | Other Debt Facilities - EUROIMMUN [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Other Long-term Debt | €         € 25.7     € 38.2            
Fair Value, Inputs, Level 2 [Member] | 0.6 Percent Senior Unsecured Notes due in April 2021 [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Long-term Debt 334,200,000 $ 341,300,000                        
Fair Value, Inputs, Level 2 [Member] | 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]                            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                            
Long-term Debt $ 839,900,000